Extended Data Fig. 7: CAMK2–PSAT1–GPX4 axis attenuates ICB therapeutic efficacy.
From: PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation
a–c, 4T-1 cells with expression of indicated proteins were subcutaneously (a,b) or mammary pad-orthotopically (c) injected into BALB/c female mice (n = 6 per group). These mice were given anti-mPD-1 antibody (100 μg/100 µL) or control hamster IgG (100 μg/100 µL) by i.p. injection starting on the seventh day after tumor inoculation and treated every 3 days a time for a total of five treatments. Liproxstatin-1 (Lip-1) was intraperitoneally injected daily from the 4th day at a dose of 10 mg/kg until the end point at day 28 (a). Tumor volumes (top) and tumor weight (bottom) were calculated. Bioluminescence imaging (BLI) images (c, left) and quantification of BLI signals on day 28 (c, right) were shown. Data are presented as the mean ± s.d., two-tailed Student’s t test.
